Skip to main content
Premium Trial:

Request an Annual Quote

Opko Completes $1.47B Buy of Bio-Reference

NEW YORK (GenomeWeb) – Opko today announced it has completed its $1.47 billion acquisition of Bio-Reference Laboratories.

Under the terms of the deal, which was announced in June, Bio-Reference's shareholders will receive 2.75 shares of Opko for each share of BRL's common stock that they own.

Based in Elmwood Park, New Jersey, Bio-Reference is the third-largest clinical laboratory in the US. Through its GeneDx genetic sequencing laboratory and its GenPath Diagnostics oncology and women's health business unit, Bio-Reference has accumulated a significant amount of genetic and genomic data that Opko will make available to industry and academic researchers to accelerate drug discovery and clinical trial programs. 

Opko is a biopharmaceutical and diagnostics firm headquartered in Miami. Its diagnostic services will be merged with Bio-References's operations, the firms said in June.